ENTPD1 and neoplasm: CD39 inhibitors, including ARL67156 and POM-1, are effective in animal models of follicular lymphoma, sarcoma, or mouse melanoma, resulting in the partial overcoming of poor T cell response to stimulation, enhanced response to chemotherapeutic drugs, and inhibition of tumor growth, respectively (47).